2019-04-01 08:28:00 Mon ET
technology social safety nets education infrastructure health insurance health care medical care medication vaccine social security pension deposit insurance
OraSure and its subsidiary DNA Genotek specialize in the lean production of home DNA spit tubes. OraSure extracts core genetic information from microbiome saliva samples and then provides discreet DNA diagnostic test tubes and kits for liquid biopsy, hepatitis, cancer, and HIV etc. In the meantime, OraSure and its subsidiary DNA Genotek serve as a quasi-monopoly with secure economic rent protection in the new biotech market for DNA spit tubes.
As there has been a substantial increase in international demand for cost-effective and affordable DNA tests over the past decade, OraSure gains much from its R&D-driven royalty revenue. As of April 2019, the small-cap stock OraSure trades at a P/E ratio of 16.6x near most long-term average stock market benchmarks. Further, the current stock market capitalization of OraSure is almost 3.4x times total sales and 2.2x times total book assets. From a fundamental perspective, OraSure enjoys juicy profit margins: the gross profit margin of 62.5% exceeds most stock market benchmarks, and the net profit margin hovers in the healthy range of 11%-15% in recent times. As its broad biotech patents and trademarks represent fundamental competitive moats and niches, OraSure continues to dominate in the new specialty market for DNA diagnostic test tubes.
If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.
2019-01-27 12:39:00 Sunday ET
British Prime Minister Theresa May faces her landslide defeat in the parliamentary vote 432-to-202 against her Brexit deal. British Parliament rejects the M
2023-02-07 08:26:00 Tuesday ET
Michel De Vroey delves into the global history of macroeconomic theories from real business cycles to persistent monetary effects. Michel De Vroey (2016)
2019-08-03 09:28:00 Saturday ET
U.S. inflation has become sustainably less than the 2% policy target in recent years. As Harvard macro economist Robert Barro indicates, U.S. inflation has
2023-05-31 03:15:40 Wednesday ET
The U.S. further derisks and decouples from China. Why does the U.S. seek to further economically decouple from China? In recent times, th
2018-11-25 12:37:00 Sunday ET
The Chinese administration delivers a written response to U.S. demands for trade reforms. This strategic move helps trigger more formal negotiations between
2023-01-03 09:34:00 Tuesday ET
USPTO fintech patent protection and accreditation As of early-January 2023, the U.S. Patent and Trademark Office (USPTO) has approved